List of Cellerant Therapeutics patents

List of Cellerant Therapeutics patents

List of Fox Chase Cancer Center (company) patents

List of Foundation Medicine patents

List of Rubius Therapeutics patents

List of Omni Ai, Inc. patents

Online food ordering venture capital investors

Patents where

Current Assignee

Name

is

Cellerant Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 8715619 Compositions and methods for treating haematological proliferative disorders of myeloid origin	Patent 8715619 was granted and assigned to Cellerant Therapeutics on May, 2014 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	8715619	May 6, 2014
	‌ US Patent 8709715 Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof	Patent 8709715 was granted and assigned to Cellerant Therapeutics on April, 2014 by the United States Patent and Trademark Office.		Cellerant Therapeutics		United States Patent and Trademark Office	8709715	April 29, 2014
	‌ US Patent 8841418 Antibodies that specifically bind to TIM3	Patent 8841418 was granted and assigned to Cellerant Therapeutics on September, 2014 by the United States Patent and Trademark Office.		Cellerant Therapeutics		United States Patent and Trademark Office	8841418	September 23, 2014
	‌ US Patent 9631026 Antibodies that specifically bind to TIM3	Patent 9631026 was granted and assigned to Cellerant Therapeutics on April, 2017 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	9631026	April 25, 2017
	‌ US Patent 10898580 Isoquinolidinobenzodiazepines	Patent 10898580 was granted and assigned to Cellerant Therapeutics on January, 2021 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	10898580	January 26, 2021
	‌ US Patent 9850314 Antibodies specific for CLL-1	Patent 9850314 was granted and assigned to Cellerant Therapeutics on December, 2017 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	9850314	December 26, 2017
	‌ US Patent 8481315 Methods of expanding myeloid cell populations and uses thereof	Patent 8481315 was granted and assigned to Cellerant Therapeutics on July, 2013 by the United States Patent and Trademark Office.		Cellerant Therapeutics		United States Patent and Trademark Office	8481315	July 9, 2013
	‌ US Patent 9504694 Isoquinolidinobenzodiazepines	Patent 9504694 was granted and assigned to Cellerant Therapeutics on November, 2016 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	9504694	November 29, 2016
	‌ US Patent 9371390 Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof	Patent 9371390 was granted and assigned to Cellerant Therapeutics on June, 2016 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	9371390	June 21, 2016
	‌ US Patent 10301394 Antibodies that specifically bind to TIM3	Patent 10301394 was granted and assigned to Cellerant Therapeutics on May, 2019 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	10301394	May 28, 2019
	‌ US Patent 9974864 Isoquinolidinobenzodiazepines	Patent 9974864 was granted and assigned to Cellerant Therapeutics on May, 2018 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	9974864	May 22, 2018
	‌ US Patent 8383095 Methods and compositions for enhancing engraftment of hematopoietic stem cells	Patent 8383095 was granted and assigned to Cellerant Therapeutics on February, 2013 by the United States Patent and Trademark Office.		Cellerant Therapeutics		United States Patent and Trademark Office	8383095	February 26, 2013
	‌ US Patent 9163090 Antibodies specific for CLL-1	Patent 9163090 was granted and assigned to Cellerant Therapeutics on October, 2015 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	9163090	October 20, 2015
	‌ US Patent 8877495 Methods of expanding myeloid cell populations and uses thereof	Patent 8877495 was granted and assigned to Cellerant Therapeutics on November, 2014 by the United States Patent and Trademark Office.		Cellerant Therapeutics		United States Patent and Trademark Office	8877495	November 4, 2014
	‌ US Patent 10350218 Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers	Patent 10350218 was granted and assigned to Cellerant Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Cellerant Therapeutics	Cellerant Therapeutics		United States Patent and Trademark Office	10350218	July 16, 2019

15 results

0 selected

15 results

0 selected